Volume 15, Issue 4 (Winter 2018)
Sci J Iran Blood Transfus Organ 2018, 15(4): 235-238 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abdellah Y, Pourfathollah A, Eslama H, Raouf M. The role of access to affordable and quality assured blood and blood products for achieving Universal Health Coverage. Sci J Iran Blood Transfus Organ 2018; 15 (4) :235-238
URL: http://bloodjournal.ir/article-1-1245-en.html
URL: http://bloodjournal.ir/article-1-1245-en.html
Abstract: (3395 Views)
Abstract
Background and Objectives
Patients with thalassemia are one of the at risk groups for acquiring Hepatitis C virus (HCV) infection. They need to be transfused regularly. High prevalence of this virus in thalassemia population, complications of HCV infection and the important effect of HCV genotype determination in treatment of the virus were the reasons for performing this research. The aims of the present study were to detect thalassemia patients with chronic infection and determinate the HCV subtypes distribution in this group.
Materials and Methods
The study was concluded on 120 specimens for HCV antibody from thalassemia patients in Tehran and Amol cites. After sequencing of PCR products, determination of HCV subtypes was performed by construction of phylogenic trees. c2, t, Fisher exact test and SPSS 22 have been used for data analysis.
Results
The results showed that 67 (55/8 %) of the 120 specimens were positive for HCV RNA, 34 (28.3%) from Tehran and 33 (27.5%) from Amol. 65 specimens could be genotyped. Subtype 1a accounted for 53/8 % (n=35), 3a for 30.7 % (n = 20), 1b for 13/8 % (n = 9) and 4a for 1/7 % (n = 1) of infected cases.
Conclusions
Implementation of effective strategies for detection of thalassemia patients, with HCV chronic infection in thalassemia centers is necessary. The predominance of genotype 1 among thalassemia patients is important in treatment of these patients because genotype 1 indicates lower rate of sustained viral response to current therapy (Interferon and Ribavirin ) compare to HCV genotype 2 and 3.
Background and Objectives
Patients with thalassemia are one of the at risk groups for acquiring Hepatitis C virus (HCV) infection. They need to be transfused regularly. High prevalence of this virus in thalassemia population, complications of HCV infection and the important effect of HCV genotype determination in treatment of the virus were the reasons for performing this research. The aims of the present study were to detect thalassemia patients with chronic infection and determinate the HCV subtypes distribution in this group.
Materials and Methods
The study was concluded on 120 specimens for HCV antibody from thalassemia patients in Tehran and Amol cites. After sequencing of PCR products, determination of HCV subtypes was performed by construction of phylogenic trees. c2, t, Fisher exact test and SPSS 22 have been used for data analysis.
Results
The results showed that 67 (55/8 %) of the 120 specimens were positive for HCV RNA, 34 (28.3%) from Tehran and 33 (27.5%) from Amol. 65 specimens could be genotyped. Subtype 1a accounted for 53/8 % (n=35), 3a for 30.7 % (n = 20), 1b for 13/8 % (n = 9) and 4a for 1/7 % (n = 1) of infected cases.
Conclusions
Implementation of effective strategies for detection of thalassemia patients, with HCV chronic infection in thalassemia centers is necessary. The predominance of genotype 1 among thalassemia patients is important in treatment of these patients because genotype 1 indicates lower rate of sustained viral response to current therapy (Interferon and Ribavirin ) compare to HCV genotype 2 and 3.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
